CO6680668A2 - Ensayos biomarcadores para detectar o medir inhibición de actividad quinasa tor - Google Patents

Ensayos biomarcadores para detectar o medir inhibición de actividad quinasa tor

Info

Publication number
CO6680668A2
CO6680668A2 CO13038904A CO13038904A CO6680668A2 CO 6680668 A2 CO6680668 A2 CO 6680668A2 CO 13038904 A CO13038904 A CO 13038904A CO 13038904 A CO13038904 A CO 13038904A CO 6680668 A2 CO6680668 A2 CO 6680668A2
Authority
CO
Colombia
Prior art keywords
tor kinase
kinase activity
detect
measure inhibition
biomarker assays
Prior art date
Application number
CO13038904A
Other languages
English (en)
Inventor
Lilly Wong
Shuichan Xu
jian hua Ding
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of CO6680668A2 publication Critical patent/CO6680668A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

La invención proporciona métodos para detectar y/o medir la inhibición de la actividad quinasa TOR en un sujeto y su uso asociado con el mismo. El método comprende el uso de citometría de flujo para medir la cantidad de 4EBP1 fosforilada en una muestra biológica del sujeto antes y después de la administración de un inhibidor de quinasa TOR. La invención tiene utilidad en la inhibición de quinasa TOR en un sujeto para el tratamiento de cáncer.
CO13038904A 2010-07-30 2013-02-26 Ensayos biomarcadores para detectar o medir inhibición de actividad quinasa tor CO6680668A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36945510P 2010-07-30 2010-07-30

Publications (1)

Publication Number Publication Date
CO6680668A2 true CO6680668A2 (es) 2013-05-31

Family

ID=45527332

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13038904A CO6680668A2 (es) 2010-07-30 2013-02-26 Ensayos biomarcadores para detectar o medir inhibición de actividad quinasa tor

Country Status (21)

Country Link
US (1) US20120028972A1 (es)
EP (1) EP2598885B1 (es)
JP (1) JP2013535684A (es)
KR (1) KR20130136970A (es)
CN (1) CN103119445B (es)
AU (1) AU2011282553B2 (es)
BR (1) BR112013002279A2 (es)
CA (1) CA2807147A1 (es)
CO (1) CO6680668A2 (es)
CR (1) CR20130070A (es)
EC (1) ECSP13012461A (es)
ES (1) ES2591135T3 (es)
MX (1) MX337907B (es)
MY (1) MY170983A (es)
NI (1) NI201300013A (es)
NZ (1) NZ606495A (es)
RU (1) RU2587040C2 (es)
SG (1) SG187659A1 (es)
UA (1) UA111724C2 (es)
WO (1) WO2012016113A1 (es)
ZA (1) ZA201300921B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100048914A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
EP3023433A1 (en) 2009-02-05 2016-05-25 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
MY183661A (en) 2011-10-19 2021-03-05 Signal Pharm Llc Treatment of cancer with tor kinase inhibitors
ES2742398T3 (es) 2012-02-24 2020-02-14 Signal Pharm Llc Métodos para tratar el cáncer de pulmón no microcítico usando una terapia de combinación de inhibidores de TOR quinasa
US20130245026A1 (en) * 2012-03-15 2013-09-19 Signal Pharmaceuticals, Llc Treatment of cancer with tor kinase inhibitors
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
AU2014207641A1 (en) 2013-01-16 2015-08-06 Signal Pharmaceuticals, Llc Substituted Pyrrolopyrimidine Compounds, compositions thereof, and methods of treatment therewith
EP2968370A4 (en) 2013-03-14 2016-09-21 Univ Maryland AGENT FOR ANDROGEN RECEPTOR DOWNWARD CONTROL AND USES THEREOF
AU2014254050B2 (en) 2013-04-17 2018-10-04 Signal Pharmaceuticals, Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
US9474757B2 (en) * 2013-04-17 2016-10-25 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
MX2015014455A (es) * 2013-04-17 2016-07-21 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y n-(3-(5-fluoro-2-(4-(2-metoxietoxi)fenilamino)pirimidin-4-ilamino )fenil)acrilamida para tratar cancer.
BR112015026257B1 (pt) * 2013-04-17 2022-12-20 Signal Pharmaceuticals, Llc Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
MX2015014590A (es) * 2013-04-17 2016-03-03 Signal Pharm Llc Tratamiento de cancer con dihidropirazino-pirazinas.
NZ631082A (en) * 2013-04-17 2017-06-30 Signal Pharm Llc Methods for treating cancer using tor kinase inhibitor combination therapy
BR112015026238A8 (pt) * 2013-04-17 2019-12-24 Signal Pharm Llc composto dihidropirazino-pirazina, composição farmacêutica que o compreende, uso do composto, métodos para inibir ou medir a fosforilação e para inibir a atividade da proteína quinase, bem como kit
KR102382576B1 (ko) * 2013-04-17 2022-04-08 시그날 파마소티칼 엘엘씨 암 치료를 위한 TOR 키나제 억제제 및 IMiD 화합물을 포함하는 조합요법
CA2912627C (en) 2013-05-29 2022-03-15 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
BR112016002970A2 (pt) 2013-08-12 2017-09-12 Tokai Pharmaceuticals Inc biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
ES2823756T3 (es) 2014-04-16 2021-05-10 Signal Pharm Llc Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2015160882A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
JP2017520603A (ja) 2014-07-14 2017-07-27 シグナル ファーマシューティカルズ,エルエルシー 置換ピロロピリミジン化合物を使用するがんの治療方法及びその組成物
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
KR20200019229A (ko) 2017-06-22 2020-02-21 셀진 코포레이션 B형 간염 바이러스 감염을 특징으로 하는 간세포 암종의 치료

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135298B2 (en) * 2003-03-26 2006-11-14 The Burnham Institute For Medical Research Screening assay for agents that alter target of Rapamycin activity
EP1899463A4 (en) * 2005-05-09 2009-11-25 Ariad Pharma Inc BIOMARKERS FOR EVALUATING THE PROBABILITY THAT A TUMOR IS SENSITIVE TO A MTOR INHIBITOR
GB0509748D0 (en) * 2005-05-13 2005-06-22 Univ Glasgow Materials and methods relating to cell based therapies
EP1951724B1 (en) * 2005-11-17 2011-04-27 OSI Pharmaceuticals, Inc. FUSED BICYCLIC mTOR INHIBITORS
AR057960A1 (es) * 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
RU2478635C2 (ru) * 2006-10-19 2013-04-10 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Гетероарильные соединения, содержащие их композиции и способы лечения с применением этих соединений
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway

Also Published As

Publication number Publication date
RU2587040C2 (ru) 2016-06-10
MX337907B (es) 2016-03-28
EP2598885B1 (en) 2016-07-20
RU2013108840A (ru) 2014-09-10
ZA201300921B (en) 2014-04-30
CN103119445A (zh) 2013-05-22
ES2591135T3 (es) 2016-11-25
AU2011282553A1 (en) 2013-03-14
WO2012016113A1 (en) 2012-02-02
MY170983A (en) 2019-09-23
CR20130070A (es) 2013-05-20
SG187659A1 (en) 2013-03-28
AU2011282553B2 (en) 2015-04-02
CA2807147A1 (en) 2012-02-02
BR112013002279A2 (pt) 2018-04-24
CN103119445B (zh) 2015-10-21
NZ606495A (en) 2014-08-29
US20120028972A1 (en) 2012-02-02
JP2013535684A (ja) 2013-09-12
NI201300013A (es) 2013-04-19
EP2598885A4 (en) 2014-03-26
UA111724C2 (uk) 2016-06-10
EP2598885A1 (en) 2013-06-05
MX2013001293A (es) 2013-04-29
KR20130136970A (ko) 2013-12-13
ECSP13012461A (es) 2013-03-28

Similar Documents

Publication Publication Date Title
CO6680668A2 (es) Ensayos biomarcadores para detectar o medir inhibición de actividad quinasa tor
BR112018069849A2 (pt) kit, dispositivo e método para a detecção de câncer pancreático precoce ou de lesão precursora do câncer pancreático
EP4349248A3 (en) Apparatus for determining damaged tissue using sub-epidermal moisture measurements
ES2570380T3 (es) Método para determinar la aptitud de inhibidores de EZH2 humano en tratamiento
MX2019015016A (es) Ensayos para la deteccion de una sola molecula y uso de los mismos.
EP3971299A3 (en) Colorectal cancer detection kit or device, and detection method
ECSP13012394A (es) Nuevas formas de dosificación de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
BR112016028944A2 (pt) kit ou dispositivo para a detecção de câncer do trato biliar e método de detecção
CL2012003048A1 (es) Compuestos derivados de n-fenil-3-(1h-pirazol-4-il)quinoxalin-6-amina, inhibidores de tirosino quinasa fgfr; proceso de preparación; composición farmacéutica; y su uso en la prevención o tratamiento de cáncer.
MX349561B (es) Método para detectar nucleosomas que contienen variantes de histonas.
SMT201600231B (it) Metodo per misurare la concentrazione di alcool nel respiro e relativo apparecchio
MX2013007835A (es) Combinacion de sirosingopina e inhibidores mitocondriales para el tratamiento de cancer e inmunosupresion.
MX2016005313A (es) Deteccion de la actividad de corte de una enzima.
MX348655B (es) Biomarcadores para pronosticar sensibilidad a tratamientos contra el cancer.
TN2015000325A1 (en) Markers associated with wnt inhibitors
BR112014015037A2 (pt) método, sistema e dispositivo eletrônico para determinar a trajetória de um fluxo aquoso, e sonda autônoma
MX2012011326A (es) Sistema y metodo para evaluacion de farmaco anticanceroso candidato.
GB201206323D0 (en) Methods and arrays for use in the same
BR112015020054A2 (pt) Método de detectar resistência aos efeitos terapêuticos de um inibidor de akt em uma célula cancerosa
TR201902547T4 (tr) Oksi̇dati̇f stresli̇ hastalarda parati̇roi̇d hormonunun ölçüm araçlari ve yöntemleri̇
BR112013010481A2 (pt) método para medir a capacitância de um sensor que tem uma capacitância e uma resistência e uso
CY1121482T1 (el) Ευαισθητη πολυπλεκτικη ανοσοδοκιμασια για τους διαλυτους υποδοχεις των αυξητικων παραγοντων των ινοβλαστων
CL2009001907A1 (es) Metodo de deteccion precoz de cancer gastrico que comprende detectar la presencia de marcadores especificos de cancer gastrico en muestras de plasma.
IT1402187B1 (it) Dispositivo di misura e relativo procedimento di misura.
IN2014DN07866A (es)